Is IMV Inc. (IMVIQ) a Buy, Sell, or Hold?
OTC : IMVIQ
IMV Inc.
$1e-05 USD
$0.0 (-90.91%)
- Volume
- 2K
- Average Volume
- 30
- Market Capitalization
- $117
- P/E Ratio
- -0.18
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.93
Company Overview
OTC
Andrew Hall
Biotechnology
Healthcare
IMVIQ
63
CA
USD
Liquidity Metrics
-4.38
2.93
2.93
2.25
0.00
Sales & Valuation
-$
0.00
-1.00
-0.27
-4.13
Profitability
-$4.55
-$37.99M
0.00%
0.00%
-495.17%
-117.99%
P/E Metrics
-0.18
-0.02
-0.02
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-11.97
1/9
$18.17M
$31.35M
$37.95M
-$38.47M
Key Metrics (TTM)
$16.98M
0.00
-0.47
2.93
-495.17%
-172.47%
-557.86%
-370.36%
0 days
Company Executives
| Name | Title |
|---|---|
| Jeremy R. Graff | Chief Scientific Officer |
| Andrew Hall | Chief Executive Officer & Director |
| Brittany Davison | Chief Accounting Officer, Corporate Secretary & Director |
| Delphine Davan | Senior Director of Communications & Investor Relations |
| Stephan Fiset | Vice President of Clinical Research |
Poll Results
No votes yet today — be the first to share your view!
About IMV Inc. (OTC:IMVIQ) Stock
IMV Inc. is a biotechnology firm focused on developing cancer treatments, currently in the clinical trial phase. It leverages its proprietary DPX immune-modulating technology platform to create a range of therapeutic candidates aimed at both solid and blood-related cancers. Its primary investigational therapy, maveropepimut-S, is an immunotherapy built on the DPX platform, designed to target cells that express survivin. This compound is currently undergoing Phase II clinical evaluations for conditions such as diffuse large B-cell lymphoma, ovarian cancer, as well as solid tumors of the bladder, liver, and those exhibiting high microsatellite instability (MSI-H). Additionally, maveropepimut-S is in Phase I trials for breast cancer. Other developments include DPX-SurMAGE, which is in Phase I ... trials for bladder cancer, along with candidates like DPX-COVID-19 and DPX-RSV, which are being explored for infectious diseases. Previously known as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its headquarters in Dartmouth, Canada.
Frequently Asked Questions
-
What is the current IMV Inc. (IMVIQ) stock price?
-
IMV Inc.(OTC:IMVIQ) stock price is $1e-05 in the last trading session. During the trading session, IMVIQ stock reached the peak price of $5 while $1.0E was the lowest point it dropped to. The percentage change in IMVIQ stock occurred in the recent session was --90.91% while the dollar amount for the price change in IMVIQ stock was -$0.0.
-
IMVIQ's industry and sector of operation?
-
The OTC listed IMVIQ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMVIQ?
-
Jeremy R. Graff | Chief Scientific Officer
Andrew Hall | Chief Executive Officer & Director
Brittany Davison | Chief Accounting Officer, Corporate Secretary & Director
Delphine Davan | Senior Director of Communications & Investor Relations
Stephan Fiset | Vice President of Clinical Research -
How many employees does IMVIQ have?
-
Number of IMVIQ employees currently stands at 63. IMVIQ operates from 130 Eileen Stubbs Avenue, Dartmouth, NS B3B 2C4, CA.
-
Link for IMVIQ official website?
-
Official Website of IMVIQ is: https://www.imv-inc.com
-
How do I contact IMVIQ?
-
IMVIQ could be contacted at phone #902 492 1819 and can also be accessed through its website. IMVIQ operates from 130 Eileen Stubbs Avenue, Dartmouth, NS B3B 2C4, CA.
-
How many shares of IMVIQ are traded daily?
-
The average number of IMVIQ shares traded daily for last 3 months was 30.
-
What is the market cap of IMVIQ currently?
-
The market value of IMVIQ currently stands at $117 with its latest stock price at $1e-05